VCANBIO(SH:600645) Zheng Quan Ri Bao Wang·2026-02-13 13:14Core Viewpoint - Zhongyuan Qihua (600645) is advancing its clinical research in innovative therapies, focusing on treatments for idiopathic pulmonary fibrosis and chronic periodontitis [1] Group 1: Clinical Trials - The company's wholly-owned subsidiary, Wuhan Guanggu Pharmaceutical, is conducting a Phase I clinical trial for VUM02 injection aimed at treating idiopathic pulmonary fibrosis (IPF) [1] - The company holds a stake in Beijing Sanyouli, which is collaborating with Capital Medical University on a Phase II clinical trial for "human dental pulp mesenchymal stem cell injection" to treat chronic periodontitis [1] Group 2: Regulatory Compliance - The company's stem cell clinical research projects have been registered with the National Health Commission/NMPA and the Logistics Support Department of the Central Military Commission [1]